Australia - English - Department of Health (Therapeutic Goods Administration)

air liquide healthcare pty ltd - oxygen, quantity: 1 l/l - gas, medicinal - excipient ingredients: - for respiratory delivery where there is a requirement for medicinal oxygen to treat or prevent hypoxemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

air liquide healthcare pty ltd - carbon dioxide, quantity: 1 ml/ml - gas, medicinal - excipient ingredients: - as an anaesthetic supplement in various clinical circumstances to maintain optimum blood carbon levels, facilitate blind intubations and rapidly increase depth of anaesthesia with volatile agents. as a respiratory stimulant after apnoea or after relief of chronic respiratory obstruction. to prevent hypocapnia during hyperventilation. use in clinical and physiological investigations including use as insufflation gas.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - meloxicam - parenteral liquid/solution/suspension - meloxicam ungrouped active 20.0 mg/ml - musculoskeletal system

New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - flufenacet; metribuzin - water dispersible granule - flufenacet 240 g/kg; metribuzin 175 g/kg - herbicide - herbicide

New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - isoflucypram - emulsifiable concentrate (ec) - isoflucypram 50 g/litre - fungicide - fungicide

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 100 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who are homozygous for the f508del mutation in the cftr gene limitations of use the efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 100 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who are homozygous for the f508del mutation in the cftr gene limitations of use the efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.

Israel - English - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.